Athira Pharma Q3 net loss narrows, exploring strategic alternatives

LeonaBio

06/11/2025 21:16

Overview

Athira Q3 net loss decreases significantly compared to last year

Company continues exploring strategic alternatives to maximize stockholder value

Athira presents promising Phase 1 trial results for drug candidate ATH-1105

Outlook

Athira plans to advance ATH-1105 into ALS patient trials

Company continues to explore strategic alternatives to maximize stockholder value

Result Drivers

R&D EXPENSES - R&D expenses decreased significantly to $2.8 mln from $17.9 mln in the same period last year

G&A EXPENSES-  G&A expenses were $4.1 million for the quarter ended September 30, 2025, compared to $7.6 million for the quarter ended September 30, 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$1.68
Q3 Net Income
-$6.61 mln
Q3 Operating Expenses
$6.87 mln
Q3 Operating Income
-$6.87 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Press Release: ID:nGNX56ZfvP

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)